Sarcopenia
Welcome,         Profile    Billing    Logout  
 46 Companies   12 Products   12 Products   17 Mechanisms of Action   756 Trials   22406 News 


«12...263264265266267268269270271272273...401402»
  • ||||||||||  Journal:  Cystathionine gamma-lyase/H S signaling facilitates myogenesis under aging and injury condition. (Pubmed Central) -  Jul 22, 2021   
    MEF2c was S-sulfhydrated at both cysteine 361 and 420 in the C-terminal transactivation domain, and blockage of MEF2c S-sulfhydration abolished the stimulatory role of H S on MEF2c/MRF4 heterodimer formation. These findings support an essential role for H S in maintaining myogenesis, presenting it as a potential candidate for the prevention of age-related sarcopenia and treatment of muscle injury.
  • ||||||||||  Clinical, Review, Journal:  Optimizing Inpatient Nutrition Care of Adult Patients with Inflammatory Bowel Disease in the 21st Century. (Pubmed Central) -  Jul 22, 2021   
    Hospitalization can further compound pre-existing malnutrition through inappropriate diet restrictions, nil per os (NPO) for endoscopy and imaging, or partial bowel obstruction, resulting in "post-hospital syndrome" after discharge and readmission. The aim of this article is to inform clinicians of the prevalence and consequences of malnutrition in IBD, as well as available screening and assessment tools for diagnosis, and to offer an organized approach to the nutritional care of hospitalized adult IBD patients.
  • ||||||||||  Clinical, Observational data, Journal:  Nutritional Status of Non-Institutionalized Adults Aged over 65. Study of Weight and Health in Older Adults (PYSMA). (Pubmed Central) -  Jul 22, 2021   
    The aim of this article is to inform clinicians of the prevalence and consequences of malnutrition in IBD, as well as available screening and assessment tools for diagnosis, and to offer an organized approach to the nutritional care of hospitalized adult IBD patients. We identify the need to reinforce the messages to the elderly aimed at maintaining adequate physical activity and assessing the quality and quantity of dinners, as well as reducing, as much as possible, the treatments that may lead to weight gain.
  • ||||||||||  [VIRTUAL] Underlying mechanisms and pharmacological approaches for treatment of sarcopenia (Studio London) -  Jul 21, 2021 - Abstract #ERS2021ERS_482;    
    This presentation will provide an overview of the underlying mechanisms and different strategies for pharmacological intervention of sarcopenia in chronic lung disease. This presentation will provide an overview of the underlying mechanisms and different strategies for pharmacological intervention of sarcopenia in chronic lung disease.
  • ||||||||||  [VIRTUAL] Malnutrition and sarcopenia assessment (Studio London) -  Jul 21, 2021 - Abstract #ERS2021ERS_481;    
    This presentation will cover the link between sarcopenia and malnutrition, and how to assess sarcopenia in chronic lung disease. This presentation will cover the link between sarcopenia and malnutrition, and how to assess sarcopenia in chronic lung disease.
  • ||||||||||  [VIRTUAL] Update on recent definitions and diagnosis of sarcopenia (Studio London) -  Jul 21, 2021 - Abstract #ERS2021ERS_480;    
    This presentation will cover the definition, prevalence, physiology and clinical correlates of sarcopenia in chronic lung disease. This presentation will cover the definition, prevalence, physiology and clinical correlates of sarcopenia in chronic lung disease.
  • ||||||||||  [VIRTUAL] SESSION 210: Sarcopenia in chronic respiratory disease: new definitions, assessment and treatment options (Studio London) -  Jul 21, 2021 - Abstract #ERS2021ERS_478;    
    This presentation will cover the definition, prevalence, physiology and clinical correlates of sarcopenia in chronic lung disease. Aims: To describe the concept of sarcopenia in chronic respiratory disease and its importance to maintain and/or optimise the benefits of pulmonary rehabilitation; to describe the assessment of sarcopenia in chronic respiratory disease; to describe how to implement and assess the treatment options for sarcopenia in chronic lung disease; to describe the effects of sarcopenia on patients undergoing pulmonary rehabilitation.
  • ||||||||||  Preclinical, Journal:  Long-term resveratrol treatment improves the capillarization in the skeletal muscles of ageing C57BL/6J mice. (Pubmed Central) -  Jul 21, 2021   
    Our data show an inverse correlation between the number of capillaries per fibre (CAF) and TAs in both control and treated type IIB fibres, and an increase of CAF in ageing SKM upon RES-treatment. The present work suggests that capillarization is one of the determinants of the development of TAs and fatigue resistance, and that RES can be considered a good candidate to counteract capillary rarefaction in the SKM tissue.
  • ||||||||||  Clinical, Journal:  Mobility Impairment in Patients New to Dialysis. (Pubmed Central) -  Jul 21, 2021   
    Older age, lower handgrip strength, and quality of life are risk factors for slowness. Patients at highest risk of poor gait speed can be identified at dialysis initiation to allow targeted implementation of therapeutic options.
  • ||||||||||  Journal:  Nutrition status mediates the association between cognitive decline and sarcopenia. (Pubmed Central) -  Jul 21, 2021   
    These findings demonstrate that the negative effects of cognitive decline on sarcopenia were mediated by nutrition status. We therefore postulate that maintaining a good nutrition status delays the negative effects of cognitive decline on sarcopenia in older adults.
  • ||||||||||  Journal:  Late-onset neuromuscular disorders in the differential diagnosis of sarcopenia. (Pubmed Central) -  Jul 21, 2021   
    In geriatric patients with a focal or asymmetrical muscular weakness and atrophy, sarcopenia assessment should be extended with patient's history of disease course. Furthermore, concomitant diseases, analysis of serum creatine kinase, electrophysiological examination, and in selected patients muscle biopsy and gene analysis is needed to rule out a late-onset neuromuscular disorder.
  • ||||||||||  Enrollment closed, Trial completion date, Trial primary completion date:  Sarcopenia and Outcomes of Neuroplasty in Lumbar Spinal Stenosis (clinicaltrials.gov) -  Jul 21, 2021   
    P=N/A,  N=79, Active, not recruiting, 
    Furthermore, concomitant diseases, analysis of serum creatine kinase, electrophysiological examination, and in selected patients muscle biopsy and gene analysis is needed to rule out a late-onset neuromuscular disorder. Recruiting --> Active, not recruiting | Trial completion date: Nov 2021 --> Nov 2022 | Trial primary completion date: May 2021 --> May 2022
  • ||||||||||  Review, Journal:  Sarcopenia: What Is the Origin of This Aging-Induced Disorder? (Pubmed Central) -  Jul 20, 2021   
    We argue that preventive measures are likely to be more effective to counter act aging-induced disorders than efforts to treat manifest clinical conditions. To achieve compliance with a prescription of preventive measures that may be life-long, we need to identify reliable predictors to design rational and convincing interventions.
  • ||||||||||  [VIRTUAL] Diagnosis and treatment of malnutrition (Room 1) -  Jul 20, 2021 - Abstract #UEGW2021UEGW_5405;    
    US examination of the anterior thigh was useful to detect sarcopenia and obesity in RA patients. Learning objectives: · Definition and criteria of malnutrition · Tools for sarcopenia assessment · Identifying which patient is at risk (including patients with obesity) · Artificial nutrition (enteral and parenteral): Indications and modalities of administration · Ethical considerations regarding artificial nutrition
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date:  Role of MicroRNAs on Age and Contraction-induced Skeletal Muscle Growth (clinicaltrials.gov) -  Jul 20, 2021   
    P=N/A,  N=30, Active, not recruiting, 
    Since newly developed sarcopenia after surgical resection had an influence on the overall survival, patients with high sarcopenia risks after curative gastrectomy may require early nutritional support. Trial completion date: Jan 2021 --> Jan 2022 | Trial primary completion date: Jan 2021 --> Jan 2022
  • ||||||||||  Trial completion date, Trial primary completion date:  RENAMUS 19: FGF19 and Chronic Kidney Disease (clinicaltrials.gov) -  Jul 19, 2021   
    P=N/A,  N=170, Not yet recruiting, 
    Trial completion date: Jan 2021 --> Jan 2022 | Trial primary completion date: Jan 2021 --> Jan 2022 Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Dec 2022 --> Mar 2022
  • ||||||||||  Niagen (nicotinamide riboside) / ChromaDex
    Journal:  Nicotinamide Riboside Vitamin B3 Mitigated C26 Adenocarcinoma-Induced Cancer Cachexia. (Pubmed Central) -  Jul 16, 2021   
    Furthermore, NR administration significantly increased the levels of crucial enzymes involved in the biosynthesis of NAD and nicotinamide phosphoribosyl transferase and significantly inhibited the NAD-sensitive deacetylase sirtuin 1 (SIRT1). Preemptive intake of NR in patients vulnerable to cachexia can be a preemptive option to ameliorate cancer cachexia.